Get the complete picture of why Devyser RHD sets a new standard for fetal RHD screening.

• Simple by design 
  Discover how Devyser RHD’s unique single-exon assay simplifies analysis and reduces inconclusive results. With few steps and a streamlined workflow, it’s easier than ever to implement reliable fetal RHD genotyping into your lab routine. 

• Performance in clinical use 
  Backed by large-scale validation studies, Devyser RHD delivers 99.9% sensitivity and 99.95% specificity, helping avoid unnecessary prophylaxis and ensure confident clinical decisions as early as week 10 of pregnancy. 

• Trusted in practice 
  With over 100,000 pregnancies tested, 12 years of product expertise, and CE-IVDR, Risk Class D, certification, Devyser RHD is a proven, trusted solution in national screening programs and high-throughput settings. 

Don't miss this opportunity to explore how Devyser RHD shapes non-invasive RHD genotyping. 

Feel free to submit your questions beforehand if you want them addressed during the webinar.

*Disclaimer: Devyser products are distributed worldwide. Not all intended uses and applications mentioned here are available in every country. Please consult your local sales representative for details.